MBX Biosciences, Inc. Overview
MBX market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 55.88
- H
- 58.33
- L
- 55.52
- C
- 57.64
- Vol
- 34,611.00
Daily history from Sep 13, 2024
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $55.88
- Previous Close
- $56.40
- Day High
- $58.33
- Day Low
- $55.52
- 52 Week High
- $71.83
- 52 Week Low
- $23.57
- 7 Day Return
- +9.60%
- 30 Day Return
- +10.85%
- 90 Day Return
- -14.14%
- 1 Year Return
- +131.35%
- Daily Notional Volume
- $2M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.83 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $23.07 – $72.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.7B · P/B 3.84.